We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

38 hedge funds and large institutions have $8.64M invested in Aevi Genomic Medicine Inc in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less funds holding

Funds holding: 44 → 38 (-6)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

45% less capital invested

Capital invested by funds: $15.6M → $8.64M (-$6.98M)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
38
Holders Change
-6
Holders Change %
-13.64%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
7
Reduced
10
Closed
8
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$66K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$40.3K
2
VF
Virtu Financial
New York
+$25.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$24.4K
4
Jane Street
Jane Street
New York
+$13.5K
5
Morgan Stanley
Morgan Stanley
New York
+$3.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$291K
2
Millennium Management
Millennium Management
New York
-$61.4K
3
PAM
Panagora Asset Management
Massachusetts
-$45K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$45K
5
Goldman Sachs
Goldman Sachs
New York
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$6K +$3.7K +3,313 +45%
UBS Group
27
UBS Group
Switzerland
$4K -$4.12K -3,688 -42%
Simplex Trading
28
Simplex Trading
Illinois
$1K -$2.59K -2,320 -58%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$1K -$99 -89 -4%
Bank of America
30
Bank of America
North Carolina
$1K – – –
LTFS
31
Ladenburg Thalmann Financial Services
Florida
$1K – – –
TWA
32
TCI Wealth Advisors
Arizona
$1K – – –
Group One Trading
33
Group One Trading
Illinois
$1K +$1.96K +1,758 +1,758%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$1 – – –
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
– -$45K -36,690 Closed
Goldman Sachs
36
Goldman Sachs
New York
– -$38K -30,960 Closed
CDH
37
Charles D. Hyman
– -$19K -15,143 Closed
TSS
38
Two Sigma Securities
New York
– -$17K -14,138 Closed
ARTA
39
A.R.T. Advisors
New York
– -$13K -10,949 Closed
MAM
40
Meeder Asset Management
Ohio
– -$5.36K -4,800 -89%
LA
41
Legacy Advisors
Pennsylvania
– -$3K -2,450 Closed
IA
42
IFP Advisors
Florida
– -$1K -500 Closed
TRCT
43
Tower Research Capital (TRC)
New York
– +$157 +141 New
1
2

GNMX Hedge Fund Activity: Q4 2018 in Review

38 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2018, worth a combined $8.64M — down 45% from $15.6M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GNMX and 2 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $40.3K. The largest seller was Vanguard Group, cutting an estimated $291K.

  • 38 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2018, down from 44 in Q3 2018.
  • Funds reported $8.64M of Aevi Genomic Medicine Inc stock for Q4 2018, down 45% quarter-over-quarter.
  • 2 funds opened new Aevi Genomic Medicine Inc positions in Q4 2018 and 8 closed out, a net change of -6 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2018 was Renaissance Technologies, an estimated $40.3K added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2018 was Vanguard Group, an estimated $291K sold.

Based on aggregated 13F filings for Q4 2018.